The Virginia Cannabis Control Authority (CCA) is the independent political subdivision responsible for regulating cannabis in Virginia. Established under the 2021 legalization law and codified in §§ 4.1-600 et seq. of the Code of Virginia, the CCA currently oversees the medical cannabis program and will expand to regulate the full retail market once HB 642 takes effect.

Structure and Independence

The CCA is structured as an independent political subdivision of the Commonwealth — not a department or agency within the executive branch. This unusual designation gives the CCA regulatory autonomy while maintaining accountability to the legislature and the public.

Board of Directors

The CCA is governed by a 5-member Board of Directors appointed by the Governor:

• Chair: John Keohane — retired Police Chief, bringing a law enforcement perspective to cannabis regulation
• Four additional board members with backgrounds in public policy, business, health, and community advocacy

Board contact: CCABoard@cca.virginia.gov

Leadership

The CCA's day-to-day operations are led by Acting Director Jamie Patten, who oversees the agency's transition from a medical-only regulator to the comprehensive authority that will manage Virginia's entire commercial cannabis market.

Current Authority: Medical Cannabis

The CCA assumed oversight of Virginia's medical cannabis program from the Board of Pharmacy on January 1, 2024. The medical program currently includes:

• 104,840 registered patients — Virginia has no list of qualifying conditions; any patient whose practitioner determines cannabis therapy is appropriate can participate
• 23 dispensaries across 5 Health Service Areas, operated by pharmaceutical processors
• A practitioner directory for patients seeking a certifying provider
• No medical cannabis card required — patients need only a written certification from a registered practitioner plus a valid ID
• Telemedicine consultations are permitted for certifications

Expansion Under HB 642

With the passage of HB 642 in March 2026, the CCA's authority will expand dramatically to encompass the entire cannabis market:

Licensing

• Processing and approving applications for retail stores (350 cap), cultivation facilities (450), processors (60), wholesalers (25), microbusinesses (100), delivery-only, and testing labs
• Implementing the 50% social equity reservation for retail licenses
• Managing the $10 million conversion fee process for existing medical processors entering retail
• Application window opening July 1, 2026

Market Regulation

• Establishing rules for cultivation, manufacturing, distribution, retail, and delivery
• Setting product standards for potency, packaging, and labeling
• Overseeing seed-to-sale tracking systems
• Administering the tax collection framework (6% state excise + optional local taxes)

Intoxicating Hemp

• Under HB 642, the CCA will also regulate intoxicating hemp-derived products (including Delta-8 THC)
• This closes a regulatory gap that allowed unregulated, untested hemp products to be sold without age verification

Enforcement

• Conducting compliance inspections of licensed facilities
• Investigating complaints and violations
• Issuing fines, suspensions, and license revocations
• Coordinating with law enforcement on diversion and illegal market activity

CCA By the Numbers

Contacting the CCA

Challenges Ahead

As the CCA prepares to scale from overseeing 23 medical dispensaries to regulating a full commercial market, it faces several significant challenges:

• Rapid scaling. The agency must build out licensing, compliance, and enforcement capacity in a matter of months to meet the July 2026 application window and January 2027 retail launch
• Equity implementation. Ensuring the 50% social equity reservation for retail licenses results in genuine minority ownership, not equity-in-name-only arrangements
• Gray market transition. The gifting economy that emerged during the years without retail sales will need to be addressed as the legal market launches
• Medical-to-retail conversion. Managing the complex process of existing pharmaceutical processors converting to retail licenses, including the $10 million conversion fee and potential market power concerns
• Hemp regulation. Taking on oversight of the previously unregulated intoxicating hemp market simultaneously with the retail cannabis launch